Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Strides Arcolab

- PMLiVE

Allergan CEO takes issue with ‘predatory’ price increases

Saunders adds voice to drug pricing outcry saying perpetrators break “social contract”

- PMLiVE

Clinton takes aim at pharma pricing once again

Pledges to establish new enforcement powers to address “unjustified price hikes”

- PMLiVE

Teva acquires Allergan’s generics operations in $38.8bn deal

Also discloses $500m agreement to purchase the Irish firm’s distribution business

- PMLiVE

EMA suspends generic drugs on data integrity concerns

Reports by FDA and WHO find evidence of data manipulation by Semler Research Centre

EU flag

European pharma ‘to grow 3.2% per year by 2022’

Forecast predicts AbbVie’s Humira will be knocked off the top spot

Sanofi reception

Medivation softens on Sanofi takeover and opens its books

Due diligence agreement follows similar deals with Pfizer and Celgene

- PMLiVE

Biosimilar trastuzumab comparable to brand, ASCO hears

Roche’s Herceptin matched in safety and efficacy by Mylan and Biocon’s breast cancer drug

- PMLiVE

Mylan agrees to buy Sweden’s Meda for $7.2bn

Deal is set to boost its over-the-counter medicines portfolio 

- PMLiVE

Mylan buys into six biosimilars, including Orencia candidate

Deal with Momenta bolsters biosimilars pipeline for new products

EISAI

Eisai expands in China with generics company acquisition

BuysLiaoning TianYi Biological Pharmaceutical

- PMLiVE

Mylan misses Perrigo takeover deadline

Failureto take 50% stake ends near-term hopes for a bid

- PMLiVE

Rebuffed Horizon tries to replace Depomed board members

But firm says latest deal 'significantly undervalues' Depomed

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links